Article

Bimatoprost gets nod for hypotrichosis

Allergan has received FDA approval for its 0.03% bimatoprost ophthalmic solution (Latisse) as a novel treatment for hypotrichosis of the eyelashes.

Key Points

Irvine, CA-Allergan has received FDA approval for its 0.03% bimatoprost ophthalmic solution (Latisse) as a novel treatment for hypotrichosis of the eyelashes. The company markets the prostaglandin analog under a different name (Lumigan) for the treatment of glaucoma and ocular hypertension; it was approved for this use in 2001, and it was noted that patients who used it experienced eyelash growth as a side effect.

"[The new product] fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the FDA that increases the growth of eyelashes, making them longer, thicker, and darker," said Scott Whitcup, MD, Allergan's executive vice president of research and development.

To treat hypotrichosis, a patient applies the prescription to the base of the upper eyelashes once a day using a sterile, single-use, disposable applicator. The treatment takes effect in as few as 8 weeks, according to the company. To maintain the effect, patients must continue using the drug. If use is discontinued, eyelashes gradually will return to their prior length.

"I observed statistically significant differences in eyelash growth and resulting patient satisfaction," said clinical investigator Steven Fagien, MD, FACS, an oculoplastic surgeon in private practice at Aesthetic Eyelid Plastic Surgery in Boca Raton, FL. "Now that [the product] is FDA-approved, I look forward to prescribing it to my patients who will enjoy the benefits of more prominent eyelashes while I remain confident in the treatment's favorable safety profile."

Allergan indicated that it expects to launch bimatoprost as a hypotrichosis treatment nationwide in the first quarter of this year. It will be available by prescription only. The company estimates that global peak sales of the product could exceed $500 million per year. As the exclusive U.S. and foreign patent owner, Allergan obtains the rights to the use of bimatoprost and other prostaglandins and prostaglandin analogs as a treatment to stimulate eyelash growth.

Further product and prescribing information is available at http://www.latisse.com/.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.